These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

217 related articles for article (PubMed ID: 32335145)

  • 1. Establishment and Preclinical Therapy of Patient-derived Hepatocellular Carcinoma Xenograft Model.
    Wu Y; Wang J; Zheng X; Chen Y; Huang M; Huang Q; Xiao W; Wei H; Tian Z; Sun R; Sun C
    Immunol Lett; 2020 Jul; 223():33-43. PubMed ID: 32335145
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sorafenib plus memory-like natural killer cell immunochemotherapy boosts treatment response in liver cancer.
    Eresen A; Zhang Z; Yu G; Hou Q; Chen Z; Yu Z; Yaghmai V; Zhang Z
    BMC Cancer; 2024 Sep; 24(1):1215. PubMed ID: 39350084
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Establishment of a Patient-Derived Xenograft Tumor From Hepatitis C-Associated Liver Cancer and Evaluation of Imatinib Treatment Efficacy.
    Nazzal M; Sur S; Steele R; Khatun M; Patra T; Phillips N; Long J; Ray R; Ray RB
    Hepatology; 2020 Aug; 72(2):379-388. PubMed ID: 32356575
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Establishment of a hepatocellular carcinoma patient-derived xenograft platform and its application in biomarker identification.
    Hu B; Li H; Guo W; Sun YF; Zhang X; Tang WG; Yang LX; Xu Y; Tang XY; Ding GH; Qiu SJ; Zhou J; Li YX; Fan J; Yang XR
    Int J Cancer; 2020 Mar; 146(6):1606-1617. PubMed ID: 31310010
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Expanded and Activated Natural Killer Cells for Immunotherapy of Hepatocellular Carcinoma.
    Kamiya T; Chang YH; Campana D
    Cancer Immunol Res; 2016 Jul; 4(7):574-81. PubMed ID: 27197065
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Blocking CDK1/PDK1/β-Catenin signaling by CDK1 inhibitor RO3306 increased the efficacy of sorafenib treatment by targeting cancer stem cells in a preclinical model of hepatocellular carcinoma.
    Wu CX; Wang XQ; Chok SH; Man K; Tsang SHY; Chan ACY; Ma KW; Xia W; Cheung TT
    Theranostics; 2018; 8(14):3737-3750. PubMed ID: 30083256
    [No Abstract]   [Full Text] [Related]  

  • 7. Antitumor effect of vascular endothelial growth factor inhibitor sunitinib in preclinical models of hepatocellular carcinoma.
    Bagi CM; Gebhard DF; Andresen CJ
    Eur J Gastroenterol Hepatol; 2012 May; 24(5):563-74. PubMed ID: 22314934
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Vinorelbine Improves the Efficacy of Sorafenib against Hepatocellular Carcinoma: A Promising Therapeutic Approach.
    Ng WH; Soo KC; Huynh H
    Int J Mol Sci; 2024 Jan; 25(3):. PubMed ID: 38338842
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy of annexin A3 blockade in sensitizing hepatocellular carcinoma to sorafenib and regorafenib.
    Tong M; Che N; Zhou L; Luk ST; Kau PW; Chai S; Ngan ES; Lo CM; Man K; Ding J; Lee TK; Ma S
    J Hepatol; 2018 Oct; 69(4):826-839. PubMed ID: 29885413
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Establishment and characterization of 7 novel hepatocellular carcinoma cell lines from patient-derived tumor xenografts.
    Xin H; Wang K; Hu G; Xie F; Ouyang K; Tang X; Wang M; Wen D; Zhu Y; Qin X
    PLoS One; 2014; 9(1):e85308. PubMed ID: 24416385
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Predicting HCC Response to Multikinase Inhibitors With In Vivo Cirrhotic Mouse Model for Personalized Therapy.
    Huang DQ; Muthiah MD; Zhou L; Jumat H; Tan WX; Lee GH; Lim SG; Kow A; Bonney G; Shridhar I; Lim YT; Wee A; Pang YH; Soon G; Chow P; Dan YY
    Cell Mol Gastroenterol Hepatol; 2021; 11(5):1313-1325. PubMed ID: 33340714
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rational drug combination design in patient-derived avatars reveals effective inhibition of hepatocellular carcinoma with proteasome and CDK inhibitors.
    Lim JJ; Hooi L; Dan YY; Bonney GK; Zhou L; Chow PK; Chee CE; Toh TB; Chow EK
    J Exp Clin Cancer Res; 2022 Aug; 41(1):249. PubMed ID: 35971164
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Genomic characterization of a large panel of patient-derived hepatocellular carcinoma xenograft tumor models for preclinical development.
    Gu Q; Zhang B; Sun H; Xu Q; Tan Y; Wang G; Luo Q; Xu W; Yang S; Li J; Fu J; Chen L; Yuan S; Liang G; Ji Q; Chen SH; Chan CC; Zhou W; Xu X; Wang H; Fang DD
    Oncotarget; 2015 Aug; 6(24):20160-76. PubMed ID: 26062443
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combination therapy of sorafenib with mesenchymal stem cells as a novel cancer treatment regimen in xenograft models of hepatocellular carcinoma.
    Seyhoun I; Hajighasemlou S; Muhammadnejad S; Ai J; Nikbakht M; Alizadeh AA; Hosseinzadeh F; Mirmoghtadaei M; Seyhoun SM; Verdi J
    J Cell Physiol; 2019 Jun; 234(6):9495-9503. PubMed ID: 30362607
    [TBL] [Abstract][Full Text] [Related]  

  • 15. AZD6244 enhances the anti-tumor activity of sorafenib in ectopic and orthotopic models of human hepatocellular carcinoma (HCC).
    Huynh H; Ngo VC; Koong HN; Poon D; Choo SP; Toh HC; Thng CH; Chow P; Ong HS; Chung A; Goh BC; Smith PD; Soo KC
    J Hepatol; 2010 Jan; 52(1):79-87. PubMed ID: 19910069
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cancer cell-derived exosomal circUHRF1 induces natural killer cell exhaustion and may cause resistance to anti-PD1 therapy in hepatocellular carcinoma.
    Zhang PF; Gao C; Huang XY; Lu JC; Guo XJ; Shi GM; Cai JB; Ke AW
    Mol Cancer; 2020 Jun; 19(1):110. PubMed ID: 32593303
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeting Androgen Receptor (AR)→IL12A Signal Enhances Efficacy of Sorafenib plus NK Cells Immunotherapy to Better Suppress HCC Progression.
    Shi L; Lin H; Li G; Jin RA; Xu J; Sun Y; Ma WL; Yeh S; Cai X; Chang C
    Mol Cancer Ther; 2016 Apr; 15(4):731-742. PubMed ID: 26939703
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hedgehog signaling promotes sorafenib resistance in hepatocellular carcinoma patient-derived organoids.
    Wang S; Wang Y; Xun X; Zhang C; Xiang X; Cheng Q; Hu S; Li Z; Zhu J
    J Exp Clin Cancer Res; 2020 Jan; 39(1):22. PubMed ID: 31992334
    [TBL] [Abstract][Full Text] [Related]  

  • 19. DNMT3b/OCT4 expression confers sorafenib resistance and poor prognosis of hepatocellular carcinoma through IL-6/STAT3 regulation.
    Lai SC; Su YT; Chi CC; Kuo YC; Lee KF; Wu YC; Lan PC; Yang MH; Chang TS; Huang YH
    J Exp Clin Cancer Res; 2019 Nov; 38(1):474. PubMed ID: 31771617
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparing the efficacy of sunitinib with sorafenib in xenograft models of human hepatocellular carcinoma: mechanistic explanation.
    Huynh H; Choo SP; Toh HC; Tai WM; Chung AY; Chow PK; Ong R; Soo KC
    Curr Cancer Drug Targets; 2011 Oct; 11(8):944-53. PubMed ID: 21834756
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.